Thomson Medical Group (SGX:A50) Earnings Narrow Losses As Valuation Questions Return

Thomson Medical Group earnings spark fresh look at the stock

Thomson Medical Group (SGX:A50) released full year results to June 30, 2026, reporting sales of $420.08 million and a net loss of $29.7 million, alongside a narrower basic loss per share.

Against this backdrop, Thomson Medical Group’s share price has been under pressure, with the year-to-date share price return down 11.48% and the 1-year total shareholder return down 8.47%, which points to fading momentum despite the recent earnings improvement.

Compare Thomson Medical Group with other hospital and clinic operators that combine healthcare exposure with stronger balance sheets and cash flows in our curated list of list of solid balance sheet and fundamentals (440 results).

Thomson Medical Group is still loss making and the share price has already retreated this year. So, based on today’s numbers, is more of the potential upside ahead of investors or behind them in terms of valuation?

Preferred Price-to-Sales Multiple of 3.3x: Is it justified?

On Simply Wall St’s numbers Thomson Medical Group trades on a P/S of 3.3x, while the shares last closed at $0.054. That multiple sits above several key reference points, which raises questions about what investors are currently willing to pay for each dollar of sales.

The P/S ratio compares the company’s market value to its revenue and is often used for businesses like Thomson Medical Group that are still reporting losses. It tells you how much the market is pricing each dollar of current sales, regardless of profit. This can matter for hospitals and clinics that are investing heavily in capacity or new services.

For Thomson Medical Group, the P/S of 3.3x is described as expensive versus both the peer average of 2.3x and the wider SG Healthcare industry average of 2.4x. It is also above the estimated fair P/S of 2.8x that Simply Wall St’s fair ratio work suggests the market could move toward if sentiment or expectations cool from here.

Explore the SWS fair ratio for Thomson Medical Group.

Result: Price-to-Sales of 3.3x (OVERVALUED)

However, Thomson Medical Group still reports a net loss of $29.7 million and has a 5 year total shareholder return down 35.67%, which could weaken investor confidence.

Find out about the key risks to this Thomson Medical Group narrative.

Another view on Thomson Medical Group using our DCF model

The P/S of 3.3x makes Thomson Medical Group look expensive, yet our DCF model points in the opposite direction. At a share price of $0.054, the stock trades about 47.8% below the SWS estimate of future cash flow value of $0.10, which frames the picture very differently.

This gap suggests the market price could be baking in far more caution than the DCF work implies. It raises a simple question for investors: Is the current discount a sign of mispricing or a reflection of the real business risks that still need to be weighed?

Look into how the SWS DCF model arrives at its fair value.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Thomson Medical Group for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 256 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

With sentiment on Thomson Medical Group clearly mixed, this is a moment to look closely at the facts and decide where you stand. If you want a concise way to weigh both sides of the story, take a look at the 2 key rewards and 1 important warning sign.

Looking for more investment ideas beyond Thomson Medical Group?

If Thomson Medical Group has sharpened your focus, now is the time to broaden your watchlist with other stocks that match clear, disciplined criteria.

• Zero in on stronger balance sheets and steadier fundamentals by reviewing our carefully filtered list of solid balance sheet and fundamentals (440 results).
• Hunt for potential value opportunities that pair quality with attractive pricing through the focused 256 high quality undervalued stocks.
• Build your income watchlist with companies offering higher yields and resilient payouts inside the curated 421 dividend fortresses.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com